DE60222557D1 - Bioadhäsive terapeutische systeme mit verzögerter freisetzung - Google Patents

Bioadhäsive terapeutische systeme mit verzögerter freisetzung

Info

Publication number
DE60222557D1
DE60222557D1 DE60222557T DE60222557T DE60222557D1 DE 60222557 D1 DE60222557 D1 DE 60222557D1 DE 60222557 T DE60222557 T DE 60222557T DE 60222557 T DE60222557 T DE 60222557T DE 60222557 D1 DE60222557 D1 DE 60222557D1
Authority
DE
Germany
Prior art keywords
bioadhesive
terapeutic
systems
delayed release
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60222557T
Other languages
English (en)
Other versions
DE60222557T2 (de
Inventor
Jean-Marc Aiache
Dominique Costantini
Christine Chaumont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioalliance Pharma SA
Original Assignee
Bioalliance Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma SA filed Critical Bioalliance Pharma SA
Publication of DE60222557D1 publication Critical patent/DE60222557D1/de
Application granted granted Critical
Publication of DE60222557T2 publication Critical patent/DE60222557T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
DE60222557T 2001-07-23 2002-07-23 Bioadhäsive terapeutische systeme mit verzögerter freisetzung Expired - Lifetime DE60222557T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0109811A FR2827517B1 (fr) 2001-07-23 2001-07-23 Systemes therapeutiques bioadhesifs a liberation prolongee
FR0109811 2001-07-23
PCT/FR2002/002635 WO2003009800A1 (fr) 2001-07-23 2002-07-23 Systemes therapeutiques bioadhesifs a liberation prolongee

Publications (2)

Publication Number Publication Date
DE60222557D1 true DE60222557D1 (de) 2007-10-31
DE60222557T2 DE60222557T2 (de) 2008-06-19

Family

ID=8865807

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60229456T Expired - Lifetime DE60229456D1 (de) 2001-07-23 2002-07-23 Bioadhäsive therapeutische Systeme mit verzögerter Freisetzung
DE60222557T Expired - Lifetime DE60222557T2 (de) 2001-07-23 2002-07-23 Bioadhäsive terapeutische systeme mit verzögerter freisetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60229456T Expired - Lifetime DE60229456D1 (de) 2001-07-23 2002-07-23 Bioadhäsive therapeutische Systeme mit verzögerter Freisetzung

Country Status (15)

Country Link
US (5) US6916485B2 (de)
EP (2) EP1408911B1 (de)
JP (2) JP4657603B2 (de)
CN (2) CN101524337A (de)
AT (2) ATE411003T1 (de)
CA (1) CA2455633C (de)
CY (2) CY1107828T1 (de)
DE (2) DE60229456D1 (de)
DK (2) DK1408911T3 (de)
ES (2) ES2316108T3 (de)
FR (1) FR2827517B1 (de)
HK (1) HK1107516A1 (de)
IL (2) IL159842A0 (de)
PT (2) PT1792610E (de)
WO (1) WO2003009800A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827517B1 (fr) * 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
US20050054583A1 (en) * 2003-08-20 2005-03-10 Matsumoto Dental University Composition for an antifungal agent for suppressing fungal growth in an oral cavity
JP2005097271A (ja) * 2003-08-20 2005-04-14 Matsumoto Shika Univ 抗真菌剤用組成物
CN1302764C (zh) * 2005-01-10 2007-03-07 凌沛学 一种妇科用药阴道凝胶片
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) * 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8865743B2 (en) * 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
EP1837020A1 (de) * 2006-03-24 2007-09-26 Bioalliance Pharma Bioadhäsive Schleimhautträger zur langsamen Verabreichung von aktiven Substanzen
EP1972332A1 (de) * 2007-03-23 2008-09-24 BioAlliance Pharma Mukosaler, bioadhäsiver und langsam freigesetzter Träger zur Wirkstofffreisetzung
EP2211845B1 (de) 2007-10-17 2017-02-22 Laboratoire HRA Pharma Glucocorticoid-rezeptor-antagonisten wie mifepriston zur behandlung des cushing-syndroms
DK2214679T3 (da) 2007-11-13 2019-05-20 Meritage Pharma Inc Kortikosteroidsammensætninger
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US8865692B2 (en) * 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
EP2165706A1 (de) 2008-09-18 2010-03-24 BioAlliance Pharma Behandlung von Entzündungsschmerzen der Mundhöhlenschleimhäute unter Verwendung von therapeutischen mukosalen, bioadhäsiven Trägern mit verlängerter Abgabe
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US20120232043A1 (en) 2009-09-15 2012-09-13 Cemag Lubiprostone for obstetrical or gynecological applications
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
US8592434B2 (en) * 2009-12-09 2013-11-26 Bioalliance Pharma Sa Mucoadhesive buccal tablets for the treatment of orofacial herpes
EP2335690A1 (de) * 2009-12-09 2011-06-22 BioAlliance Pharma Mukoadhäsive bukkale Tabletten zur Behandlung von orofazialem Herpes
TR201810146T4 (tr) * 2009-12-09 2018-08-27 Vectans Pharma Orofasiyal herpesin tedavisine yönelik mukoz yapışmalı ağız içi tabletleri.
WO2011091892A1 (en) 2010-02-01 2011-08-04 Ulmann Andre A method for late post coital contraception using ulipristal acetate
WO2011091890A1 (en) 2010-02-01 2011-08-04 Laboratoire Hra-Pharma A method for post coital contraception in overweight for obese female subjects using ulipristal acetate
CN101822701B (zh) * 2010-06-08 2012-11-21 格特生物制药（天津）有限公司 一种治疗畜禽痢疾、肠炎的杨树花缓释片及其制备方法
FR2967575A1 (fr) * 2010-11-19 2012-05-25 Df3 Composition et formulation galenique bio-adhesive
WO2013121663A1 (ja) * 2012-02-14 2013-08-22 救急薬品工業株式会社 口腔内溶解型フィルム製剤
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
PL2872121T3 (pl) 2012-07-12 2019-02-28 SpecGx LLC Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
SG11201507260QA (en) 2013-04-10 2015-10-29 Preglem Sa Progesteron receptor modulators for use in the therapy of uterine fibroids
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (de) 2013-06-04 2018-09-05 Cellixbio Private Limited Zusammensetzungen und verfahren zur behandlung von diabetes und prädiabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
CA3047088A1 (en) 2016-12-15 2018-06-21 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
DE102019000321A1 (de) 2019-01-14 2020-07-16 Beuth Hochschule Für Technik Berlin Orale Polymerzusammensetzung mit verzögerter Freisetzung
DE102019000322A1 (de) 2019-01-14 2020-07-16 Beuth Hochschule Für Technik Berlin Polymerzusammensetzung mit antiseptischen Eigenschaften und Verfahren zur Herstellung
CN110237042A (zh) * 2019-06-04 2019-09-17 华润双鹤利民药业（济南）有限公司 硝酸咪康唑阴道片生产工艺
EP4009968A4 (de) * 2019-08-09 2023-08-16 The Board Of Trustees Of The University Of Illinois Kombinationstherapie von systemischen pilzinfektionen
FR3110079A1 (fr) * 2020-05-12 2021-11-19 Vectans Pharma Comprimé mucoadhésif pour le traitement des infections fongiques oropharyngées
DE102020007979A1 (de) 2020-12-29 2022-06-30 Charité Universitätsmedizin Institut für Mikrobiologie und Infektionsimmunologie Zusammensetzung zur Behandlung von lnfektionen mit Coronaviren

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58210007A (ja) 1982-06-02 1983-12-07 Takeda Chem Ind Ltd 上部「あ」
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4849229A (en) * 1984-03-26 1989-07-18 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
DE3433239A1 (de) * 1984-09-11 1986-03-20 Bayer Ag, 5090 Leverkusen Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4915948A (en) * 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US5330746A (en) * 1988-05-03 1994-07-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dental varnish composition, and method of use
US5160737A (en) * 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
US5116603A (en) * 1989-01-31 1992-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Oral antifungal preventative, and method of use
US4951948A (en) * 1989-04-17 1990-08-28 Peng Jung C Shock absorbing bat
FR2665357B1 (fr) * 1990-07-31 1995-03-31 Aiache Jean Marc Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee.
GB9318641D0 (en) * 1993-09-08 1993-10-27 Edko Trading Representation Compositions
ES2135723T3 (es) * 1994-03-30 1999-11-01 Gs Dev Ab Uso de esteres de acidos grasos como sustancias bioadhesivas.
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
TR199800894T2 (xx) * 1995-12-27 1998-08-21 Janssen Pharmaceutica N.V. Biyo-yap��kan kat� dozaj formlar�.
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
WO1998047499A1 (en) 1997-04-22 1998-10-29 Nippon Kayaku Kabushiki Kaisha Flutamide preparations and method for manufacturing the same
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
GB9826192D0 (en) * 1998-12-01 1999-01-20 Controlled Theraputics Scotlan Oral transmucosal delivery
FR2827517B1 (fr) * 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee

Also Published As

Publication number Publication date
ES2294170T3 (es) 2008-04-01
EP1792610B1 (de) 2008-10-15
CY1107828T1 (el) 2013-06-19
CN1547464B (zh) 2011-02-09
FR2827517A1 (fr) 2003-01-24
US7651698B2 (en) 2010-01-26
US20130310335A1 (en) 2013-11-21
DE60222557T2 (de) 2008-06-19
CA2455633A1 (fr) 2003-02-06
EP1408911B1 (de) 2007-09-19
US20030108603A1 (en) 2003-06-12
JP2004537558A (ja) 2004-12-16
HK1107516A1 (en) 2008-04-11
PT1792610E (pt) 2009-01-12
DK1408911T3 (da) 2008-01-28
ATE411003T1 (de) 2008-10-15
PT1408911E (pt) 2007-12-26
JP4657603B2 (ja) 2011-03-23
CY1108796T1 (el) 2014-04-09
IL159842A0 (en) 2004-06-20
CN101524337A (zh) 2009-09-09
DE60229456D1 (de) 2008-11-27
ATE373464T1 (de) 2007-10-15
EP1408911A1 (de) 2004-04-21
US20070160668A1 (en) 2007-07-12
US6916485B2 (en) 2005-07-12
CA2455633C (fr) 2012-05-01
DK1792610T3 (da) 2009-02-16
EP1792610A2 (de) 2007-06-06
IL159842A (en) 2010-02-17
EP1792610A3 (de) 2007-06-27
US8518442B2 (en) 2013-08-27
JP2010270142A (ja) 2010-12-02
ES2316108T3 (es) 2009-04-01
WO2003009800A1 (fr) 2003-02-06
US20050208129A1 (en) 2005-09-22
US20110039800A1 (en) 2011-02-17
CN1547464A (zh) 2004-11-17
FR2827517B1 (fr) 2003-10-24

Similar Documents

Publication Publication Date Title
DE60222557D1 (de) Bioadhäsive terapeutische systeme mit verzögerter freisetzung
ES2082723B1 (es) Formulacion farmaceutica de fluoxetina en forma dispersable.
NO2016024I1 (no) Farmasøytisk blanding eller assosisjon som inneholder som aktive ingredienser: (1) ceftazidim eller et salt derav, og (2) avibaktam eller et farmasøytisk akseptabelt salt derav
EP2311489A3 (de) Formularierung Antikörper-enthaltender Lösungen die einen Zucker als Stabilisator beinhalten.
WO2002080969A1 (fr) Remedes pour des maladies liees a l'arthrite chronique du nourrisson
MXPA03011947A (es) Formulaciones de olopatidina para administracion topica.
NO20030411L (no) Farmasöytiske sammensetninger for behandlingen av smertefulle, inflammatoriske og ulceröse tilstander av fuktige epiteloverflater slik sommukositt, stomatitt og Behcets syndrom
UA94032C2 (ru) Жидкая стабализированная композиция интерферона без hsa
NO994431L (no) Ny formulering
MXPA04003540A (es) Utilizacion de un copolimero para producir una forma galenica que contiene un peptido o proteina como agente activo.
BR9506956A (pt) Composição farmacêutica antitussígena
WO2004071156A3 (en) Use of edible acid in fast-dispersing pharmaceutical solid dosage forms
DE50105710D1 (de) Pharmazeutische, ramipril enthaltende brauseformulierung
BR0210632A (pt) Tratamento de doença parasìtica
RS49520B (sr) Antimikrobno aktivne smeše
CA2429793A1 (en) Interferon therapeutic effect enhancer
CO5251413A1 (es) Uso nuevo
WO2003005978A1 (en) Remedy against skin diseases
UA40515A (uk) Горілка "столітня"
NZ521515A (en) Composition comprising paracetamol and niflumic acid
JO2370B1 (en) Pharmaceutical formulations for the treatment of painful, inflamed and ulcerated conditions of wet epithelial surfaces such as mucositis, stomatitis and Behçet syndrome
UA40531A (uk) Горілка "гусарська оригінальна"
RU2003131618A (ru) Инсектицидный состав для борьбы с личинками оводов эга-1
WO2001062258A3 (en) Improvement of implantation rate using ff-mas
UA83996C2 (ru) Фармацевтическая гелевая композиция пептидов, способ ее получения, набор для ее получения и ее применение

Legal Events

Date Code Title Description
8364 No opposition during term of opposition